Study of the Manufacturing and Storage Processes and Clinical Applications of Cord Blood-Derived Autologous iPS Cells
First written in FY2026-H1. 3 of 4 entries say "Advanced", first in 2026-05-13. Latest entry: 2026-08-06.
No other company in this theme has enough history to compare yet.
- 2026-08-06AdvancedEarnings
「We are currently considering collaboration toward realizing a manufacturing and storage service for iPS cells for customers who store cord blood.」
Following the successful manufacture of iPS cells from long-term stored cord blood, the company continues to consider collaboration to realize a manufacturing and storage service for storage customers. - FY2026AdvancedAnnual report
「In a joint research project with 株式会社iPSポータル toward a manufacturing and storage service for autologous iPS cells derived from cord blood, we confirmed that high-quality iPS cells could be produced from cord blood that had been cryopreserved by the Company for more than 20 years, and that the stored cord blood was an excellent source.」
Verification of iPS cell production from long-term-stored cord blood progressed, and the results were presented at the regenerative medicine conference in March 2026. - 2026-05-13AdvancedEarnings presentation
「Manufacturing and storage processes for autologous iPS cells established」
The company stated that manufacturing and storage processes for autologous iPS cells had been established, representing progress from the launch of the previous joint study. - FY2026-H1First statedAnnual report
「In September 2025, the Company announced the start of a joint study with 株式会社iPSポータル on the manufacturing and storage processes and clinical applications of autologous iPS cells using cord blood.」
The Company began a new study with 株式会社iPSポータル on the manufacture, storage and clinical applications of autologous iPS cells from long-term-stored cord blood.